Webinar:

Graft Versus Host Disease: Opportunities in a Growing Market

Sponsored by: GlobalData

Focused on:

  • Graft Versus Host Disease

Date: 28 April

181

Time: 3PM London/10AM New York

The Graft versus Host Disease (GvHD) market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan). In this webinar, GlobalData will analyze the current GvHD treatment and prophylaxis landscape and provide detailed insights into the market dynamics of this newly recognized disorder. This webinar will include the evaluation of the commercial and clinical profiles of drugs in development for GvHD, and their sales projections within GvHD over a 2018–2028 forecast period.

Currently, the GvHD prophylaxis and treatment algorithm varies significantly among physicians and institutions, largely due to the current treatment options consisting of mostly off-label therapies. Over the forecast period, GlobalData expects that treatment options for GvHD patients will become more consistent as pipeline products with significant clinical evidence are approved and launched for GvHD prophylaxis and treatment.

James Mather, a Senior Healthcare Analyst at GlobalData, will present the changing GvHD prophylaxis and treatment landscape between 2018 and 2028, drawing insights from GlobalData’s recently published report, Graft Versus Host Disease: Opportunity Analysis and Forecasts to 2028. The webinar will include insights from Key Opinion Leaders (KOLs) covering the most important unmet needs for GvHD, as well as the opportunities which are likely to remain by the end of the forecast period. Dr. Heather Leach, GlobalData’s Immunology Therapy Area Director, will moderate a Q&A session following the presentation.

Presented by

James Mather,

Senior Analyst & Project Manager, Immunology

James Mather, MChem is the Senior Analyst & Project Manager for the Respiratory and Immunology competitive intelligence (CI) team at GlobalData, and is responsible for GvHD and Sjogren’s syndrome CI tracker services in addition to the respiratory competitive intelligence portfolio. Previously, James was a Senior Analyst in GlobalData’s Infectious Diseases team, during which time he authored and contributed to reports covering a wide range of neurological, infectious disease topics as well as contributing to thematic research projects which assessed the impact of emerging technologies and regulatory changes on the healthcare industry. Prior to joining GlobalData, James received his MChem degree in Chemistry from Loughborough University; during these studies he was awarded the departmental prize for Organic and Biomedical Chemistry.

Heather Leach,

Director of Immunology

Heather Leach, PhD, is the Director of Immunology at GlobalData in New York City. Heather has 10 years of basic research experience in molecular biology and immunology and several years’ experience as an analyst and consultant for the biopharmaceutical industry. Previously, Heather served as GlobalData’s Director of Oncology and Hematology. Prior to joining GlobalData’s oncology group, she worked as an analyst in both immunology and neurology, and as a consultant for a boutique life sciences consulting firm in New York City. She has worked in various academic and pharmaceutical research labs at the University of Connecticut, Boston University School of Medicine, and Pfizer, covering human diseases such as sepsis, systemic sclerosis, and idiopathic pulmonary fibrosis. Heather holds a Bachelor’s degree in Molecular and Cell Biology from the University of Connecticut, and a PhD in Pathology and Cell and Molecular Biology from Boston University School of Medicine.

Key Learning Objectives

  • Learn how GlobalData expects the GvHD landscape to change between 2018 and 2028 across the seven major markets (US, France, Germany, Italy, Spain, the UK and Japan).
  • Gain insight on the late-stage pipeline for GvHD, including which products GlobalData expects to succeed, and why.
  • Learn which unmet needs KOLs identified in the GvHD prophylaxis and treatment landscape, and whether or not they are likely to be met by the current pipeline .
  • Identify which companies are set to be the major players in the GvHD market during the forecast period.

Audience

  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers